eCARTv5 Clinical Deterioration Suite (“eCART”) vs Infera

AgileMD's eCARTv5 is praised for its intuitive interface and seamless integration with EHRs, which streamlines workflows and reduces clinician workload. Users highlight its user-friendly design and reliable performance in delivering critical clinical insights. Infera's description focuses on providing patient-specific recommendations at the point of care and streamlining physician workflows, but specific user experience feedback beyond general ease of use for light therapy devices (which appears to be a different product line) is not readily available for its clinical decision support system.

eCARTv5 is an FDA-cleared SaMD that continuously assesses and predicts the risk of clinical deterioration (death or ICU transfer) in hospitalized adult patients, with strong evidence from multicenter prospective validation studies showing superior performance over other early warning scores. Infera provides patient-specific recommendations and HCC coding solutions, which are valuable for improving documentation and reducing audit risk, but it does not have FDA clearance and its clinical validation studies for patient outcomes are not as prominently detailed in the provided information.

Both tools require prospective customers to contact the vendor for tailored quotes, making a direct comparison of pricing and value difficult. Neither company publicly lists specific pricing tiers or transparent cost structures. While Infera offers a free trial, AgileMD's value proposition is strongly tied to its FDA clearance and robust clinical validation, which can justify a premium.

AgileMD's eCARTv5 is designed for integration with EHR systems, has HIPAA compliance, a BAA, and FDA clearance, indicating a strong readiness for enterprise deployment in hospitals and health systems. It has been deployed in over 400 hospitals and used by over 150,000 clinical users. Infera also integrates with EHRs and is HIPAA compliant, but its target size is primarily group practices and payer-owned providers, and it lacks FDA clearance for its clinical decision support system, which may be a barrier for larger hospital systems.

eCARTv5 leverages AI-powered gradient-boosted machine learning for continuous patient risk assessment and early warning, a sophisticated approach that has undergone extensive validation. Its FDA clearance as a Software as a Medical Device (SaMD) for predicting clinical deterioration also highlights its innovative standing in the regulatory landscape. Infera focuses on AI-powered clinical decision support and risk adjustment, which is innovative, but the specific advanced AI methodologies or unique technological breakthroughs are not as clearly articulated as with eCARTv5's predictive modeling.

AgileMD offers comprehensive support including email, phone, chat, FAQ, help desk, knowledge base, and 24/7 live support, along with various training options and extensive publications. While Infera mentions its care pathways are well-researched and referenced, specific details about their support channels and documentation for their clinical decision support system are not as extensively detailed in the provided information.